Skip to main content

Table 2 Seven-point ordinal categorical primary endpoint of the CLARITY trial

From: Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial

Category

Description

1

Not hospitalised with no limitation on activities

2

Not hospitalised with some limitation on activities

3

Hospitalised, not requiring supplemental oxygen

4

Hospitalised, requiring supplemental oxygen

5

Hospitalised, requiring non-invasive mechanical ventilation or high-flow nasal cannular (HFNC) therapy

6

Hospitalised, requiring mechanical ventilation ± additional organ support

7

Died